BR112021022916A2 - Bactérias produtoras de ácido lático frutofílico - Google Patents
Bactérias produtoras de ácido lático frutofílicoInfo
- Publication number
- BR112021022916A2 BR112021022916A2 BR112021022916A BR112021022916A BR112021022916A2 BR 112021022916 A2 BR112021022916 A2 BR 112021022916A2 BR 112021022916 A BR112021022916 A BR 112021022916A BR 112021022916 A BR112021022916 A BR 112021022916A BR 112021022916 A2 BR112021022916 A2 BR 112021022916A2
- Authority
- BR
- Brazil
- Prior art keywords
- acid producing
- fructophilic
- producing bacteria
- lactic acid
- lactic
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract 4
- 235000014655 lactic acid Nutrition 0.000 title abstract 2
- 239000004310 lactic acid Substances 0.000 title abstract 2
- 229930091371 Fructose Natural products 0.000 abstract 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 2
- 239000005715 Fructose Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 241000193749 Bacillus coagulans Species 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/52—Propionic acid; Butyric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/54—Acetic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/031965 WO2020231397A1 (fr) | 2019-05-13 | 2019-05-13 | Bactéries produisant de l'acide lactique fructophile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022916A2 true BR112021022916A2 (pt) | 2022-01-18 |
Family
ID=73289609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022916A BR112021022916A2 (pt) | 2019-05-13 | 2019-05-13 | Bactérias produtoras de ácido lático frutofílico |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3969606A4 (fr) |
| JP (1) | JP7469332B2 (fr) |
| KR (1) | KR20220007660A (fr) |
| CN (1) | CN114207107A (fr) |
| AU (1) | AU2019445706B2 (fr) |
| BR (1) | BR112021022916A2 (fr) |
| CA (1) | CA3140038A1 (fr) |
| MX (1) | MX2021013902A (fr) |
| WO (1) | WO2020231397A1 (fr) |
| ZA (1) | ZA202110214B (fr) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767203B2 (en) * | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| JP4888622B2 (ja) | 2001-06-04 | 2012-02-29 | キユーピー株式会社 | オリゴヌクレオチド及びこれをプライマーとして用いたバチルスコアグランスの検出方法 |
| AU2006314188B2 (en) * | 2005-11-16 | 2014-01-16 | Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh | Agent for use in the case of fructose intolerance |
| JP2010148402A (ja) | 2008-12-24 | 2010-07-08 | Toyo Shokuhin Kenkyusho | バチルス・コアギュランスを検出する方法および検出用オリゴヌクレオチド |
| BR112013015255A2 (pt) * | 2010-12-17 | 2016-09-13 | Gervais Danone Sa | cepas de lactococcus lactis para uso em aperfeiçoamento de condição digestiva |
| JP5892580B2 (ja) | 2011-04-14 | 2016-03-23 | 国立大学法人 琉球大学 | 新規乳酸菌及びｌ−乳酸の製造方法及び乳酸菌を含む食品および薬品 |
| US9371548B2 (en) * | 2011-04-14 | 2016-06-21 | Industrial Technology Research Institute | Method for producing butyric acid, butanol and butyrate ester |
| US9596861B2 (en) | 2013-12-24 | 2017-03-21 | Sami Labs Limited | Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof |
| JP6486612B2 (ja) | 2014-05-27 | 2019-03-20 | 株式会社山田養蜂場本社 | 抗アレルギー作用を有する乳酸菌及びその用途 |
| SG11201700006UA (en) | 2014-08-29 | 2017-01-27 | Muhammed Majeed | Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof |
-
2019
- 2019-05-13 CN CN201980097794.9A patent/CN114207107A/zh active Pending
- 2019-05-13 CA CA3140038A patent/CA3140038A1/fr active Pending
- 2019-05-13 WO PCT/US2019/031965 patent/WO2020231397A1/fr unknown
- 2019-05-13 JP JP2021568485A patent/JP7469332B2/ja active Active
- 2019-05-13 KR KR1020217040516A patent/KR20220007660A/ko unknown
- 2019-05-13 AU AU2019445706A patent/AU2019445706B2/en active Active
- 2019-05-13 EP EP19929028.9A patent/EP3969606A4/fr active Pending
- 2019-05-13 MX MX2021013902A patent/MX2021013902A/es unknown
- 2019-05-13 BR BR112021022916A patent/BR112021022916A2/pt unknown
-
2021
- 2021-12-09 ZA ZA2021/10214A patent/ZA202110214B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3969606A1 (fr) | 2022-03-23 |
| KR20220007660A (ko) | 2022-01-18 |
| AU2019445706A1 (en) | 2022-01-06 |
| MX2021013902A (es) | 2022-03-11 |
| WO2020231397A1 (fr) | 2020-11-19 |
| JP7469332B2 (ja) | 2024-04-16 |
| ZA202110214B (en) | 2023-06-28 |
| EP3969606A4 (fr) | 2023-01-11 |
| CN114207107A (zh) | 2022-03-18 |
| AU2019445706B2 (en) | 2024-04-18 |
| JP2022536252A (ja) | 2022-08-15 |
| CA3140038A1 (fr) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2524432T3 (es) | Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas | |
| AR106800A1 (es) | Composiciones que comprenden cepas bacterianas | |
| NO974371L (no) | Epitelialadhesive lactobacilli | |
| ES2550059T3 (es) | Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales | |
| BR112014030202A2 (pt) | microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados | |
| RU2018106510A (ru) | Композиция молочнокислых бактерий для применения в лечении инфекций, обусловленных Propionibacterium acnes, и, в частности, акне | |
| WO2019066599A3 (fr) | Nouvelles bactéries d'acide lactique et leur utilisation | |
| MX337762B (es) | Tratamiento a alta temperatura de corta duracion que genera preparaciones microbiales con perfiles anti-inflamatorios. | |
| BRPI0516489A (pt) | produtos da bactéria do ácido lático e da bìfida-bactéria com um alto grau de dispersibilidade | |
| BRPI0609093A8 (pt) | Processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma | |
| Nicoletti et al. | Non‑pathogenic microflora of a spring water with regenerative properties | |
| WO2019098810A3 (fr) | Nouvelles bactéries lactiques et leur utilisation | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| WO2022272248A9 (fr) | Modulateurs de cbl-b et leurs utilisations | |
| Lahiri et al. | Bacillus clausii as an adjuvant therapy in acute childhood diarrhoea | |
| BR112022019932A2 (pt) | Composições para saúde metabólica | |
| Wang et al. | Quercetin reversed lipopolysaccharide-induced inhibition of osteoblast differentiation through the mitogen‑activated protein kinase pathway in MC3T3-E1 cells | |
| Wang | The entropy perspective on human illness and aging | |
| BR112021022916A2 (pt) | Bactérias produtoras de ácido lático frutofílico | |
| Pang et al. | Sarcopenia and nonalcoholic fatty liver disease: New evidence for low vitamin D status contributing to the link | |
| BR112022008559A2 (pt) | Bactéria produtora de serotonina | |
| EP3932416A4 (fr) | Composition pour améliorer, prévenir ou traiter des maladies osseuses ou des maladies métaboliques, comprenant une nouvelle souche lactobacillus sakei cvl-001 et son milieu de culture | |
| MX2020013857A (es) | Bacterias bifidobacterium bifidum no viables y usos de las mismas. | |
| Jerome et al. | A case of aerococcus urinae vertebral osteomyelitis | |
| Riffat | Prevalence, Antibiotic Susceptibility Pat-tern and Demographic Factors Related to Methicillin Resistant Staphy-lococcus aureus in Lahore, Pakistan |